Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Svetlana Agapov

Nurse Practitioner, Gerontology Lewes, DE Nurse Practitioner

NPI 1952088668 CMS profile 11493544

16295 Willow Creek Rd, Lewes, DE 19958

Open in the dashboard

General payments

$2,651

118 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Svetlana Agapov of Lewes, DE is reported in the CMS Open Payments database as having received $2,651 across 118 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,371 63
2024 General $926 39
2023 General $354 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Svetlana Agapov
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Svetlana Agapov were reported at $1,371. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Svetlana Agapov Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $133 $44–$396 $132
2022 $0 $142 $48–$452 $149
2023 $354 $158 $53–$482 $160
2024 $926 $171 $55–$533 $164
2025 $1,371 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Amgen Inc. $503 17 payments
  2. Pfizer Inc. $491 25 payments
  3. Novartis Pharmaceuticals Corporation $341 18 payments
  4. Novo Nordisk Inc $247 4 payments
  5. AstraZeneca Pharmaceuticals LP $217 11 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $111 7 payments
  7. Merck Sharp & Dohme Corporation $108 5 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $105 4 payments
  9. Scpharmaceuticals Inc. $104 5 payments
  10. Esperion Therapeutics, Inc. $59 3 payments
  11. Other $363 19 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $2,651 118 payments
Products named General payments · program years 2023–2025
  1. VYNDAQEL $303 9 payments
  2. LEQVIO $258 14 payments
  3. REPATHA Cardiovascular $238 9 payments
  4. ELIQUIS $188 16 payments
  5. Repatha Cardiology $174 4 payments
  6. VERQUVO $151 7 payments
  7. Ozempic $124 1 payment
  8. FARXIGA $114 6 payments
  9. LifeVest $105 4 payments
  10. FUROSCIX $104 5 payments
  11. Other $817 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

2,481

Median for Nurse Practitioner: 389

Drug cost

$701,314

Median for Nurse Practitioner: $21,885

Branded share of claims

28.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 304 $389,311
Xarelto Rivaroxaban Brand 71 $81,382
Jardiance Empagliflozin Brand 52 $65,038
Entresto Sacubitril/Valsartan Brand 37 $53,343
Farxiga Dapagliflozin Propanediol Brand 29 $34,471
Multaq Dronedarone Hcl Brand 12 $19,765
Repatha Sureclick Evolocumab Brand 13 $13,359
Repatha Syringe Evolocumab Brand 11 $12,849
Metoprolol Succinate Generic 360 $6,265
Flecainide Acetate Generic 36 $2,694

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$100,674

Medicare's payments for the services billed

Medicare patients

831

Average age 75

Services billed

2,074

417 women, 414 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 50%
Diabetes 31%
Atrial fibrillation 31%
Chronic kidney disease 26%
Depression 22%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $174
$174 24 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $39
  • PFIZER INC. $21
$60 304 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $57
$57 37 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $56
$56 29 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $50
$50 52 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

118 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record